U.S. scientists have discovered that pediatric low-grade gliomas — a type of brain cancer that can occur in children — are generally softer than normal…

A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…

The U.S. Food and Drug Administration (FDA) has approved the cell therapy Aucatzyl (obecabtagene autoleucel) to treat adults with relapsed or refractory precursor B-cell acute…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-108, an experimental virus-based therapy that Mustang Bio is developing for…

Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…

A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who…

Arcellx and Kite Pharma are planning to launch a Phase 3 clinical trial, dubbed iMMagine-3, to test their cell therapy anitocabtagene…

At its 15th annual gala, held in New York City this April, the International Myeloma Foundation (IMF) raised more than $675,000 — monies the…

A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…